Texas Children's Hospital, Department of Pharmacy, 6621 Fannin Street, MC 2-2510, Houston, TX 77030, USA.
Clin J Am Soc Nephrol. 2011 Apr;6(4):856-63. doi: 10.2215/CJN.08110910. Epub 2011 Jan 6.
Acute kidney injury (AKI) in hospitalized children results in increased patient morbidity and mortality. Nephrotoxic-medication exposure is a common cause of AKI. Currently, no data exist to quantify the risks of developing AKI for various nephrotoxic medications in children. The primary aim of the current study is to assess for a potential association between nephrotoxic medications and the risk of developing AKI in hospitalized noncritically ill children with no pre-existing renal insufficiency.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective case-control study in pediatric hospitalized noncritically ill patients aged 1 day to 18 years. The cases were patients who developed AKI, as defined by the pediatric modified RIFLE (pRIFLE) criteria; patients without AKI served as controls and were matched by age category, gender, and disease state.
561/1660 (33.8%) patients identified for inclusion had AKI (441 category "R," 117 category "I," three category "F"); 357 cases were matched with 357 controls. Patients with AKI had longer length of hospital stay and increased hospital costs. Patients with AKI had exposure to more nephrotoxic medications for a longer period of time compared with controls. Odds of exposure for at least one nephrotoxic medication was significant for development of AKI. Exposure to more nephrotoxic medications was associated with an increased risk of AKI.
Increasing exposure to three or more nephrotoxic medications places pediatric patients at greater risk of acute kidney injury with resultant increased hospital costs and patient morbidity.
住院儿童的急性肾损伤(AKI)会增加患者的发病率和死亡率。肾毒性药物暴露是 AKI 的常见原因。目前,尚无数据可量化各种肾毒性药物在儿童中引起 AKI 的风险。本研究的主要目的是评估在没有预先存在的肾功能不全的住院非危重病儿童中,肾毒性药物与发生 AKI 的风险之间是否存在潜在关联。
设计、地点、参与者和测量方法:我们对住院非危重病儿童(年龄 1 天至 18 岁)进行了回顾性病例对照研究。病例组为符合儿科改良 RIFLE(pRIFLE)标准的 AKI 患者;无 AKI 的患者为对照组,并按年龄、性别和疾病状态进行匹配。
在纳入的 1660 名患者中,有 561 名(33.8%)患者发生 AKI(441 例为“R”类别,117 例为“I”类别,3 例为“F”类别);357 例病例与 357 例对照相匹配。与对照组相比,AKI 患者的住院时间更长,住院费用更高。与对照组相比,AKI 患者接受的肾毒性药物种类更多,时间更长。至少使用一种肾毒性药物与 AKI 的发生显著相关。暴露于更多的肾毒性药物与 AKI 风险增加相关。
增加三种或更多肾毒性药物的暴露会使儿科患者发生急性肾损伤的风险增加,从而导致住院费用增加和患者发病率增加。